Anastrozole is a potent non-steroidal aromatase inhibitor that selectively inhibits aromatase. It is the first aromatase inhibitor approved by the US Food and Drug Administration as an adjuvant hormonal therapy in early-stage breast cancer. With most patients needing to take anastrozole for two to five years, it is important for physicians to understand the clinical pharmacology of anastrozole. Anastrozole has excellent oral bioavailability and is widely distributed throughout the body. It is extensively metabolised by the liver, with a half-life of 40-50 hours. Anastrozole is primarily excreted through the faecal route. Steady-state concentrations are achieved after seven days of once-daily administration. The standard dosage of anastrozole is 1mg/day orally. No dose adjustments are necessary based on hepatic or renal dysfunction. No significant drug-drug interaction has been reported with anastrozole use. This article is to summarise the existing knowledge of the pharmacokinetics of anastrozole.
It is estimated that two-thirds of the invasive breast cancers will be hormone-receptor-positive and will require long-term adjuvant hormonal therapy. The recommended duration of adjuvant AI therapy is usually two to five years. With the recommended treatment period being up to five years in the adjuvant setting, it is important for physicians to understand the clinical pharmacology of some of the commonly used AIs. 
Aromatase Inhibitor Development

Clinical Pharmacology of Anastrozole
Mechanism of Action
Anastrozole is a potent non-steroidal AI, also called a type II AI. AIs are divided into two types based on the method by which aromatase is inhibited. Type I AI drugs are steroidal, and the only type I drug currently available is exemestane. Type I AIs bind irreversibly to aromatase and cause permanent inactivation. Type II AIs are non-steroidal.
Anastrozole and letrozole are the currently available type II drugs. Type II AIs bind reversibly to aromatase by competing with the endogenous ligands for the active site of aromatase. They do this by forming a reversible bond to the haem iron atom in the active site. 22 
Standard Dose
The standard dose of anastrozole is 1mg/day -this dose recommendation resulted from two dose-finding studies conducted in healthy post-menopausal women. 23 In one study, volunteers took 3mg anastrozole daily for 10 days and in the other study volunteers took either 0.5 or 1mg anastrozole daily for 14 days. This was done to assess both the pharmacokinetics of anastrozole and the oestrogen-lowering effect of anastrozole. All three doses resulted in >80% reduction of oestradiol concentrations for up to 144 hours after the last dose of anastrozole. Further comparison of volunteers with oestradiol concentrations below the detection limit suggested that 1mg daily is required to achieve the maximal oestrogen suppression.
In addition, serum concentrations of gonadotrophins or adrenal steroids were not affected by anastrozole administration. 23 Another two studies comparing the effect of 1 versus 10mg/day anastrozole with megestrol acetate 40mg four times daily on post-menopausal women with advanced breast cancer showed that the 10mg dose of anastrozole did not result in greater clinical benefit. 24, 25 As a result of these studies, anastrozole 1mg/day became the recommended therapeutic dose.
Pharmacokinetics
Animal studies with radio-labelled anastrozole have shown that anastrozole has good bioavailability when administered orally. 26 A human study later confirmed that it takes two to three hours after oral administration for anastrozole to reach maximal concentration. 23 Food intake does not significantly affect steady-state serum concentration of the drug. 22 Once absorbed, anastrozole is widely distributed throughout the body, with about 40% being bound to plasma proteins. 27 The pharmacokinetics of anastrozole is linear and does not change with repeated dosing. 28 Anastrozole is extensively metabolised in the liver through N-dealkylation, hydroxylation and glucuronidation to produce three major metabolites, which account for 95% of the metabolites created. 27 Triazole is the major circulating metabolite of anastrozole and it is inactive. 28 The other two metabolites are a glucuronide conjugate of hydroxyanastrozole and a glucuronide of anastrozole itself.
Anastrozole is primarily excreted through the faecal route. As hepatic metabolism accounts for 85% of anastrozole elimination, anastrozole pharmacokinetics have been studied in patients with liver cirrhosis resulting from alcohol abuse. Compared with subjects with normal hepatic function, the oral clearance of anastrozole in patients with stable liver cirrhosis was 30% lower. The plasma concentration of anastrozole was, however, in the same range as that observed in subjects with normal hepatic function. As a result, there is no dose adjustment required in patients with stable hepatic insufficiency. 28 About 10% of the anastrozole dose is excreted unchanged in the urine. Sixty per cent is excreted as metabolites in the urine. 28 
Drug-Drug Interactions
Anastrozole is extensively metabolised in the liver. However, the metabolic pathway has not been elucidated. In vitro studies demonstrated that anastrozole inhibited CYP1A2, CYP2C8/9 and CYP3A4 (with magnitudes in descending order) at concentrations unlikely to be achieved at therapeutic doses, but had no effect on CYP2A6 or CYP2D6. 30 Clinically significant drug-drug interactions are therefore unlikely but may occur if the patient is taking medicines that interact with the cytochrome P450 system.
The ATAC trial included a third arm of combined tamoxifen and anastrozole. This combination was not better than tamoxifen alone, but was inferior to anastrozole alone. A substudy of the ATAC trial showed that concurrent administration of anastrozole and tamoxifen lowered the concentration of anastrozole by 27% (90% confidence interval 20-33%; p<0.001). This was despite the fact that anastrozole suppression did not correlate with systemic oestradiol suppression. 31 In addition, the authors' group recently showed that simvastatin is unlikely to alter the pharmacokinetics of anastrozole in a clinically meaningful way. 32 It was found that 14-day treatment with simvastatin had no statistically The Clinical Pharmacology of Anastrozole with gefitinib and anastrozole in a 63-year-old woman. 35 The study hypothesised the possibility of drug-drug interactions through CYP450, but concluded that this interaction was unlikely as the pharmacokinetics of gefitinib are not altered by CYP3A4 inhibitors. 36 In 
